Trial Profile
Phase II Study of Panitumumab, Nab-paclitaxel, and Carboplatin for Patients With Primary Inflammatory Breast Cancer (IBC) Without HER2 Overexpression
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Oct 2022
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Panitumumab (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil
- Indications Carcinoma; Inflammatory breast cancer
- Focus Therapeutic Use
- 20 Sep 2022 Status changed from active, no longer recruiting to completed.
- 29 Jun 2022 Planned primary completion date changed from 1 Nov 2021 to 1 Nov 2022.
- 14 May 2019 Planned End Date changed from 1 Nov 2021 to 1 Nov 2022.